Pharvaris (PHVS) Cash from Financing Activities (2020 - 2026)
Pharvaris' (PHVS) quarterly Cash from Financing Activities came in at -$72017.2 in Q1 2026, up 9.25% YoY from -$65917.1 in Q1 2025, and down 122.79% on a QoQ basis from $316027.3 in Q4 2025.
Analysis
Pharvaris (PHVS) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Cash from Financing Activities data on file, last reported at -$72017.2 in Q1 2026.
- Quarterly Cash from Financing Activities rose 9.25% year-over-year to -$72017.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $187.8 million (up 9464.31% YoY) and the FY2025 annual result came in at $181.5 million, up 6163.71% from the prior year.
- Cash from Financing Activities fell to -$72017.2 in Q1 2026, from $316027.3 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $69456.2 billion in Q2 2023 to a low of -$69434.8 billion in Q3 2023.
- A 5-year average of $1.3 billion and a median of $316027.3 in 2025 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 728626264.9% in 2023, down 524286449879.51% in 2023.
- Tracing PHVS's Cash from Financing Activities over 5 years: stood at -$163045.7 in 2022, then jumped by 172816.54% to $281.6 million in 2023, then tumbled by 99.79% to $604998.1 in 2024, then slumped by 47.76% to $316027.3 in 2025, then sank by 122.79% to -$72017.2 in 2026.
- The last three Cash from Financing Activities figures came in at -$72017.2 (Q1 2026), $316027.3 (Q4 2025), and $187.6 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Pharvaris | 2.10 Bn | 1.73 Bn | 85,072.10 | 123.06 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 123.06 Mn |
| Mar 31, 2026 | -72,017.25 |
| Dec 31, 2025 | 316,027.34 |
| Sep 30, 2025 | 187.56 Mn |
| Jun 30, 2025 | -25,921.88 |
| Mar 31, 2025 | -79,361.53 |
| Dec 31, 2024 | 604,998.11 |
| Sep 30, 2024 | -1,228.32 Bn |
| Jun 30, 2024 | 1,204.46 Bn |
| Mar 31, 2024 | 863,703.23 |
| Dec 31, 2023 | 281.61 Mn |
| Sep 30, 2023 | -69,434.84 Bn |
| Jun 30, 2023 | 69,456.21 Bn |
| Mar 31, 2023 | -60,914.29 |
| Dec 31, 2022 | -163,045.73 |
| Sep 30, 2022 | -8,896.31 Bn |
| Jun 30, 2022 | 9,414.98 Bn |
| Mar 31, 2022 | -123,598.56 |
| Dec 31, 2021 | -708,527.56 |
| Sep 30, 2021 | -18,353.25 |